Please assess the completion status of the following clinical trial:

Trial Title: Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* • Overweight/obese (BMI \>25) females 18 years to 45 years of age, who experienced gestational diabetes (GDM) during recent (within 12 months) pregnancy~  * postpartum metabolic abnormalities determined by a 75 g oral glucose tolerance test (Inclusive of prior GDM women with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or both (IFG/IGT) postpartum)~ * Completed lactation~ * Using adequate contraception during study period unless sterilized~ * Written consent for participation in the study~Exclusion Criteria:~* Cholestasis during the past pregnancy~* Any hepatic diseases in the past (viral hepatitis, toxic hepatic damage, jaundice of unknown etiology), gallstones, abnormal liver function tests or renal impairment (elevated serum creatinine levels or abnormal creatinine clearance~* Presence of significant systemic disease, heart problems including congestive heart failure, history of pancreatitis, or diabetes mellitus (Type 1 or 2)~* Renal impairment (e.g., serum creatinine levels ≥1.4 mg/dL for women, or eGFR \<60)~* Significantly elevated triglyceride levels (fasting triglyceride \> 400 mg %)~* Untreated or poorly controlled hypertension (sitting blood pressure \>160/95mm Hg)~* Prior history of a malignant disease requiring chemotherapy~* Known hypersensitivity or contraindications to use of insulin sensitizers such as metformin or thiazolidinediones~* History of hypersensitivity reaction to dapagliflozin or other SGLT2 inhibitors (e.g. anaphylaxis, angioedema, exfoliative skin conditions)~* Current use of metformin, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors or weight loss medications (prescription or OTC)~* Uncontrolled thyroid disease (documented normal TSH) or hyperprolactinemia~* Liver enzymes (serum alanine aminotransferase \[ALT\] and/or aspartate aminotransferase \[AST\] ) levels exceeding more than twice normal lab values~* Use of drugs known to exacerbate glucose tolerance~* History of diabetes or prior use of medications to treat diabetes except GDM~* Currently lactating~* Eating disorders (anorexia, bulimia) or gastrointestinal disorders~* Suspected pregnancy (documented negative serum pregnancy test within 72 hours before first dose of study drug), desiring pregnancy in next 6 months, breastfeeding, or known pregnancy in last 2 months~* Active or prior history of substance abuse (smoke or tobacco use within past 3 years) or significant intake of alcohol or history of alcoholism~* Patient not willing to use adequate contraception during study period and up to 4 weeks after last dose of study drug (unless sterilized).~* Debilitating psychiatric disorder such as psychosis or neurological condition that might confound outcome variables~* Inability or refusal to comply with protocol~* Not currently participating or having participated in an experimental drug study in previous three months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- DAPA/MET Extended Release (XR) (Type: EXPERIMENTAL): Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
- Dapaglifloxin (Type: ACTIVE_COMPARATOR): Dapagliflozin- 10 mg once daily before first meal for 24 weeks
- Metformin XR (Type: ACTIVE_COMPARATOR): Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the morning (AM), 1000 mg in the evening ( PM) for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).